Multiple kinase inhibitors targeting the key oncogenic and vascular endothelial growth factor (VEGF) in thyroid cancer can prolong progression-free survival and are currently used for the treatment of refractory thyroid cancer (4). The gene discussed is VEGFA; the disease is thyroid cancer.